Interleukin-2 (IL2)

DRUG2 trials

Conditions

AdenocarcinomasAdenosquamous CarcinomaAdvanced NSCLCMetastatic Non-small Cell Lung CancerNon Small Cell Lung CancerNon-Small Cell Lung CancerRecurrent Non Small Cell Lung CancerSquamous Cell Carcinoma

Phase 1

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

CompletedNCT03215810

H. Lee Moffitt Cancer Center and Research InstituteAdenocarcinomas, Adenosquamous Carcinoma, Advanced NSCLC +3

Start: 2017-10-11End: 2023-06-09Updated: 2023-07-24

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

RecruitingNCT05681780

H. Lee Moffitt Cancer Center and Research InstituteNon Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer

Start: 2023-03-10End: 2027-12-01Target: 20Updated: 2026-09-16

Journal for ImmunoTherapy of Cancer2025-04-016 citations

A Phase I Trial of Atezolizumab and Varlilumab in Combination With Radiation in Patients With Metastatic NSCLC.

2024-05-161 citations

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types

Journal for ImmunoTherapy of Cancer2021-10-0161 citations

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.

2021-08-12321 citations

280 Both tumor intrinsic and extrinsic factors contribute to TIL resistance in lung cancer patients

Regular and Young Investigator Award Abstracts2020-11-011 citations

Abstract CT056: Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial

Cancer Research2020-08-1525 citations

Interleukin-2 (IL2)

Sponsors

Conditions

Phase 1

Related Papers